These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35152459)

  • 1. Confirmatory adaptive group sequential designs for single-arm phase II studies with multiple time-to-event endpoints.
    Danzer MF; Terzer T; Berthold F; Faldum A; Schmidt R
    Biom J; 2022 Feb; 64(2):312-342. PubMed ID: 35152459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive group sequential survival comparisons based on log-rank and pointwise test statistics.
    Feld J; Faldum A; Schmidt R
    Stat Methods Med Res; 2021 Dec; 30(12):2562-2581. PubMed ID: 34641702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On sample size determination in multi-armed confirmatory adaptive designs.
    Wassmer G
    J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
    Zhou H; Chen C; Sun L; Yuan Y
    Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
    Schmidli H; Bretz F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interval and point estimation in adaptive Phase II trials with binary endpoint.
    Nhacolo A; Brannath W
    Stat Methods Med Res; 2019 Sep; 28(9):2635-2648. PubMed ID: 29921157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-arm Phase II cancer survival trial designs.
    Wu J
    J Biopharm Stat; 2016; 26(4):644-56. PubMed ID: 26098141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-stage phase II survival trial design.
    Wu J; Chen L; Wei J; Weiss H; Chauhan A
    Pharm Stat; 2020 May; 19(3):214-229. PubMed ID: 31749311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
    Cotterill A; Whitehead J
    Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.
    Jaki T; Hampson LV
    Stat Med; 2016 Feb; 35(4):522-33. PubMed ID: 26456537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible designs for phase II comparative clinical trials involving two response variables.
    Bersimis S; Sachlas A; Papaioannou T
    Stat Med; 2015 Jan; 34(2):197-214. PubMed ID: 25274584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study.
    Bayar MA; Le Teuff G; Koenig F; Le Deley MC; Michiels S
    Stat Methods Med Res; 2020 Jun; 29(6):1483-1498. PubMed ID: 31354106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.